Valink Therapeutics, a biotechnology company developing next-generation oncology therapeutics focused on bispecific antibody-drug conjugates (bsADCs) and complementary treatment modalities, announced the successful closing of an $11.8 million pre-A funding round. The round was led by redalpine, with participation from new investors LongeVC and Oxford Science Enterprises, alongside continued support from existing investors RV Invest, p53 Invest, and Hoxton Ventures.
The new funding will accelerate development of Valink’s pipeline of first-in-class cancer therapeutics and support the company’s expansion in the United States, where it has established headquarters in Cambridge, Massachusetts. And fhe funding will be used to advance Valink’s oncology programs toward key preclinical milestones and to further develop its proprietary drug discovery platform and V-gate technology.
Valink’s bsADC platform is designed to overcome critical limitations of traditional ADCs by combining innovative targeting strategies with more precise and efficient payload delivery. Through this approach, the company aims to enhance both therapeutic efficacy and safety, ultimately improving outcomes for patients with cancer and other serious diseases. Beyond bsADCs, Valink is exploring multispecific ADCs, multifunctional agonists, and protein-based therapeutic platforms that broaden its ability to treat multiple cancer types, including solid tumors such as colorectal cancer.
The company’s V-gate framework represents a new paradigm in antibody-drug conjugate design, allowing for fine-tuned control over target selection and synergistic biological effects. This flexibility enables Valink to generate therapeutics that can address complex disease mechanisms with greater precision, potentially expanding the therapeutic index of ADC-based treatments.
With a growing transatlantic presence and strong investor backing, Valink is positioned to advance its oncology programs into preclinical development and establish itself as a leader in bispecific and multispecific drug conjugate innovation. The company’s expansion into Cambridge underscores its commitment to bridging European and U.S. scientific ecosystems to accelerate breakthrough cancer therapies.
KEY QUOTES:
“We are grateful to redalpine and our syndicate of new and existing investors for their confidence in our vision and strategy. This financing strengthens our position as a leader in next-generation bispecific ADCs and supports the advancement of our oncology pipeline toward key milestones. Our V-gate approach and proprietary drug discovery engine expand the frontier of antibody drug conjugates, offering the potential for first-in-class medicines to address areas of high unmet need in oncology and beyond.”
Arne Scheu, DPhil, Co-Founder and Chief Executive Officer of Valink Therapeutics
“At redalpine, we back technologies that reshape paradigms. Valink’s discovery platform and V-gate approach represent a compelling advancement on traditional ADC strategies — unlocking new therapeutic possibilities by fusing programmable biology and a novel framework for target synergy. We’re excited to lead this round and support Valink’s mission to address real-world disease biology with precision and adaptability.”
Michael Sidler, Founding Partner at redalpine and Member of Valink Therapeutics’ Board of Directors
